Why are Higher CD34+ Cell Doses Associated with Improved Outcomes among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors - But Not for High-Risk Neuroblastoma?

Pediatr Hematol Oncol. 2024 Nov 5:1-5. doi: 10.1080/08880018.2024.2420924. Online ahead of print.

Tristan E Knight^{1

2}, Larisa Broglie^{3

4}, Akshay Sharma⁵, Muna Qayed⁶, Gregory A Yanik⁷

¹ Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA, USA.
² Division of Hematology and Oncology, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
³ CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴ Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
⁵ Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
⁶ Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA.
⁷ Mott Children's Hospital, University of Michigan Medical Center, Ann Arbor, MI, USA.

No abstract available

Keywords: Autograft; autologous hematopoietic stem cell transplant; cd34+; central nervous system tumors; neuroblastoma.